구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | anti-BCMA CAR-T |
Overview Company | Carbiogene Therapeutics Co. Ltd. |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult |
MoA Mechanism | CAR T cells (low CAR T-induced killing rate) |
MoA Biomarker | biomarkers to predict and identify factors associated with response and relapse |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.. Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks… |
Toxicology CRS | Reported |
Clinical Safety signal | Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.. Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks… |
Clinical Selected reported efficacy | ORR 97.1% |
Clinical Reported ORR | 96.6% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03548207 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | anti-BCMA CAR-T |
Overview Company | Carbiogene Therapeutics Co. Ltd. |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult |
MoA Mechanism | CAR T cells (low CAR T-induced killing rate) |
MoA Biomarker | biomarkers to predict and identify factors associated with response and relapse |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.. Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks… |
Toxicology CRS | Reported |
Clinical Safety signal | Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.. Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks… |
Clinical Selected reported efficacy | ORR 97.1% |
Clinical Reported ORR | 96.6% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03548207 |
추천 비교
추천 비교